Mechanism‐based QT/APD‐shortening therapy for potassium‐channel‐based long‐QT syndromes?
نویسندگان
چکیده
منابع مشابه
LongQt: A cardiac electrophysiology simulation platform
Mathematical modeling has been used for over half a century to advance our understanding of cardiac electrophysiology and arrhythmia mechanisms. Notably, computational studies using mathematical models of the cardiac action potential (AP) have provided important insight into the fundamental nature of cell excitability, mechanisms underlying both acquired and inherited arrhythmia, and potential ...
متن کاملLenalidomide: targeted anemia therapy for myelodysplastic syndromes.
Lenalidomide, an IMiD drug (a novel type of immunomodulating drug) was recently approved by the US Food and Drug Administration for the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS) and interstitial deletions of chromosome 5q [del(5q)]. This review examines the clinical experience from the MDS-001 and MDS-003 clinical trials that led to this approval...
متن کاملTherapy for acute heart failure syndromes.
The pharmacologic management of acute heart failure syndromes (AHFS) has changed little over the past 15 years. Traditional therapies, such as nitrates and loop diuretics, remain the mainstay of therapy, with inotropes reserved for patients who present in shock or an advanced low-output state. We review the use of these therapies in AHFS with added insights from recent clinical trials and regis...
متن کاملMyelodysplastic syndromes: therapy and outlook.
Myelodysplastic syndromes (MDS) are a diverse group of hematopoietic disorders characterized by dysplasia, peripheral cytopenias, and risk of progression to acute myeloid leukemia and death. In patients who are ineligible for potentially curative hematopoietic stem cell transplantation (HSCT), approved therapies such as lenalidomide, azacitidine, and decitabine are available for those who previ...
متن کاملLenalidomide Therapy of Myelodysplastic Syndromes
Partial or complete deletion of the long arm of chromosome 5 [del(5q)], with or without additional karyotypic abnormalities, is present in 10-15% of myelodysplastic syndromes (MDS). Anemia in these MDS responds less often to erythroblastic stimulating agents. However, immunomodulatory, anti-cytokine, and anti-angiogenic agent Lenalidomide (CC5013, Revlimid®) leads to red blood cells transfusion...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Physiologica
سال: 2020
ISSN: 1748-1708,1748-1716
DOI: 10.1111/apha.13481